Understanding the Current Rating
The Strong Sell rating assigned to Dishman Carbogen Amcis Ltd indicates a cautious stance for investors, suggesting that the stock is expected to underperform relative to the broader market and sector peers. This recommendation is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Each of these factors contributes to the overall assessment of the company’s investment potential.
Quality Assessment
As of 11 April 2026, Dishman Carbogen Amcis Ltd exhibits below-average quality metrics. The company’s long-term fundamental strength is weak, with an average Return on Capital Employed (ROCE) of just 0.97%. This low ROCE suggests that the company is not generating sufficient returns on the capital invested, which is a critical indicator of operational efficiency and profitability.
Net sales have grown at a modest annual rate of 8.10% over the past five years, reflecting limited top-line expansion. Moreover, the company’s ability to service its debt is concerning, with a high Debt to EBITDA ratio of 4.39 times. This elevated leverage increases financial risk, especially in a sector that demands consistent investment in research and development.
Quarterly profit figures further highlight challenges, with a PAT (Profit After Tax) of ₹-12.97 crores, representing a steep decline of 403.0%. Operating profit to interest coverage is low at 2.47 times, indicating limited buffer to meet interest obligations. The quarterly PBDIT (Profit Before Depreciation, Interest, and Taxes) stands at ₹113.11 crores, which is among the lowest levels recorded recently.
Valuation Perspective
Despite the weak quality metrics, the valuation grade for Dishman Carbogen Amcis Ltd is classified as very attractive. This suggests that the stock is trading at a price level that may offer value relative to its earnings and asset base. For value-oriented investors, this could present an opportunity to acquire shares at a discount to intrinsic worth, provided the company can address its operational and financial challenges.
However, it is important to note that attractive valuation alone does not guarantee positive returns, especially when other fundamental and technical indicators are negative.
Financial Trend Analysis
The financial trend for the company is currently negative. The latest data as of 11 April 2026 shows that the stock has delivered a one-year return of -16.13%, underperforming the broader BSE500 index over the same period. The year-to-date return stands at -35.82%, and the six-month return is down by 45.90%, signalling sustained downward momentum.
Institutional investor participation has also declined, with a reduction of 0.51% in their stake over the previous quarter. Institutional investors typically possess greater analytical resources and tend to reduce exposure when fundamentals deteriorate, which adds to the bearish sentiment surrounding the stock.
Technical Outlook
Technically, Dishman Carbogen Amcis Ltd is rated bearish. The stock’s price movements over recent months reflect a downtrend, with a three-month decline of 38.21% and a one-month drop of 3.46%. Although there was a modest one-week gain of 7.94% and a small positive change of 0.38% on the latest trading day, these are insufficient to offset the broader negative trend.
Bearish technicals often indicate that market sentiment is weak, and investors may expect further declines unless there is a significant change in fundamentals or external catalysts.
What This Rating Means for Investors
The Strong Sell rating from MarketsMOJO suggests that investors should exercise caution with Dishman Carbogen Amcis Ltd. The combination of weak quality, negative financial trends, and bearish technicals outweighs the appeal of its attractive valuation. For risk-averse investors, this rating signals that the stock may continue to face headwinds and could underperform relative to other opportunities in the Pharmaceuticals & Biotechnology sector.
Investors considering exposure to this stock should closely monitor quarterly results, debt servicing capacity, and any strategic initiatives aimed at improving operational efficiency. Until there is clear evidence of turnaround or stabilisation, the recommendation remains to avoid or reduce holdings in this company.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
Sector and Market Context
Within the Pharmaceuticals & Biotechnology sector, companies often face volatility due to regulatory changes, R&D outcomes, and competitive pressures. Dishman Carbogen Amcis Ltd’s current struggles are compounded by its small-cap status, which can lead to higher price volatility and lower liquidity compared to larger peers.
Investors should weigh the company’s fundamentals against sector trends and broader market conditions. While the sector may offer growth opportunities, Dishman Carbogen Amcis Ltd’s current financial and technical profile suggests it is not positioned to capitalise on these trends in the near term.
Summary of Key Metrics as of 11 April 2026
- Market Capitalisation: Smallcap
- Mojo Score: 17.0 (Strong Sell)
- Quality Grade: Below Average
- Valuation Grade: Very Attractive
- Financial Grade: Negative
- Technical Grade: Bearish
- Debt to EBITDA Ratio: 4.39 times
- ROCE: 0.97%
- PAT (Quarterly): ₹-12.97 crores
- Operating Profit to Interest Coverage: 2.47 times
- Stock Returns (1 Year): -16.13%
- Institutional Holding: 8.93%, down 0.51% last quarter
These figures collectively underpin the current Strong Sell rating and provide a comprehensive view of the company’s challenges and risks.
Investor Takeaway
For investors, the Strong Sell rating is a clear signal to approach Dishman Carbogen Amcis Ltd with caution. While the valuation appears attractive, the weak fundamentals and negative trends suggest that the stock may continue to face downward pressure. Monitoring future quarterly results and any strategic shifts will be essential for reassessing the company’s prospects.
In the meantime, investors may prefer to allocate capital to companies with stronger financial health and more positive technical momentum within the Pharmaceuticals & Biotechnology sector or other areas of the market.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
